Comparison between Colistin and Polymyxin B in the Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex
dc.contributor.author | Garcia, Rebeca Carvalho Lacerda | pt_BR |
dc.contributor.author | Rodrigues, Rodrigo Douglas | pt_BR |
dc.contributor.author | Garcia, Ester Carvalho Lacerda | pt_BR |
dc.contributor.author | Rigatto, Maria Helena da Silva Pitombeira | pt_BR |
dc.date.accessioned | 2024-10-19T06:18:52Z | pt_BR |
dc.date.issued | 2023 | pt_BR |
dc.identifier.issn | 2079-6382 | pt_BR |
dc.identifier.uri | http://hdl.handle.net/10183/280250 | pt_BR |
dc.description.abstract | Polymyxins are still widely used for the treatment of carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa bloodstream infections (BSIs). This study seeks to evaluate the impact of polymyxin B versus colistin on mortality and nephrotoxicity in BSI caused by these bacteria. We conducted a retrospective cohort study from 2014 to 2021 in Porto Alegre, Brazil. We included patients aged ≥18 years and excluded patients with polymicrobial infection or treatment for ≤48 h. The 30-day mortality was the primary outcome evaluated through Cox regression. We included 259 patients with BSI episodes: 78.8% caused by A. baumannii and 21.2% caused by P. aeruginosa. Polymyxin B did not impact mortality compared to colistin (adjusted hazard ratio (aHR), 0.82; 95% confidence interval (CI), 0.52-1.30; p = 0.40 (when adjusted for COVID-19 comorbidity, p = 0.05), Pitt bacteremia score, p < 0.01; Charlson comorbidity index, p < 0.001; time to start active antimicrobial therapy, p = 0.02). Results were maintained in the subgroups of BSI caused by A. baumannii (aHR, 0.92; 95% CI, 0.55-1.54; p = 0.74), P. aeruginosa (aHR, 0.47; 95% CI, 0.17-1.32; p = 0.15) and critical care patients (aHR, 0.77; 95% CI, 0.47-1.26; p = 0.30). Treatment with polymyxin B or colistin did not impact 30-day mortality in patients with carbapenem-resistant A. baumannii or P. aeruginosa BSI. | en |
dc.format.mimetype | application/pdf | pt_BR |
dc.language.iso | eng | pt_BR |
dc.relation.ispartof | Antibiotics. Basel. Vol. 12, no. 8 (2023), 1317, 12 p. | pt_BR |
dc.rights | Open Access | en |
dc.subject | Pseudomonas aeruginosa | en |
dc.subject | Polimixina B | pt_BR |
dc.subject | Bloodstream infection | en |
dc.subject | Acinetobacter baumannii | pt_BR |
dc.subject | Pseudomonas aeruginosa | pt_BR |
dc.subject | Colistin | en |
dc.subject | Sepse | pt_BR |
dc.subject | Polymyxin B | en |
dc.subject | Colistina | pt_BR |
dc.title | Comparison between Colistin and Polymyxin B in the Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex | pt_BR |
dc.type | Artigo de periódico | pt_BR |
dc.identifier.nrb | 001206250 | pt_BR |
dc.type.origin | Estrangeiro | pt_BR |
Este item está licenciado na Creative Commons License
-
Artigos de Periódicos (40090)Ciências da Saúde (10719)